Hengyuan Lang

USPTO Granted Patents = 11 (Patent Applications = 4)

CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 4 (Patent Applications = 4)

Average Co-Inventor Count = 4.0

ph-index = 6

Forward Citations = 199(Granted Patents)

Company Filing History:

Years Active: 2003-2013

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8580838 - 5-membered heterocycle-based p38 kinase inhibitors (2013-11-12),

2. 8410160 - 5-membered heterocycle-based P38 kinase inhibitors (2013-04-02),

3. 8242117 - 5-membered heterocycle-based p38 kinase inhibitors (2012-08-14),

4. 7863314 - 5-membered heterocycle-based p38 kinase inhibitors (2011-01-04),

5. 7825256 - Inducible nitric oxide synthase dimerization inhibitors (2010-11-02),

6. 7754726 - Benzamide derivatives as p-38 kinase inhibitors (2010-07-13),

7. 7700622 - p-38 kinase inhibitors (2010-04-20),

8. 7569571 - Substituted pyrazolo [3,4-d]pyrimidines as cytokine modulators (2009-08-04),

9. 6677452 - Pyridine carboxamide or sulfonamide derivatives and combinatorial libraries thereof (2004-01-13),

10. 6534503 - Melanocortin receptor-3 ligands to treat sexual dysfunction (2003-03-18),

11. 6515122 - Tetracyclic benzimidazole derivatives and combinatorial libraries thereof (2003-02-04),

Title: The Innovative Contributions of Hengyuan Lang in Pharmaceutical Science

Introduction

Hengyuan Lang is a distinguished inventor based in San Diego, California. With an impressive portfolio of 11 patents, he has significantly advanced the field of pharmaceutical science, particularly in developing inhibitors for p38 kinase.

Latest Patents

Lang's latest patents revolve around the development of 5-membered heterocycle-based p38 kinase inhibitors. This innovative work includes the discovery of pyrazole and imidazole-based inhibitors specifically targeting the p38α and p38β kinases. These compounds have shown promise in providing pharmaceutical compositions designed for the treatment, prevention, or amelioration of various symptoms associated with p38 kinase-mediated diseases and disorders, with a focus on inflammatory conditions.

Career Highlights

Throughout his career, Hengyuan Lang has held significant positions in prominent organizations such as Novartis AG and Lion Bioscience AG. His work at these companies has contributed to the development of cutting-edge pharmaceutical solutions and has solidified his reputation as a leader in medicinal chemistry.

Collaborations

Lang has collaborated with notable colleagues, including Jiong Lan and Yunfeng Fang. Their combined expertise and innovation have resulted in advancements that continue to impact the pharmaceutical industry positively.

Conclusion

In summary, Hengyuan Lang's contributions to the development of p38 kinase inhibitors mark a substantial achievement in the field of pharmaceuticals. His patents not only exemplify innovation but also hold potential for improving the treatment of inflammatory diseases, showcasing the vital role that inventors play in advancing scientific understanding and healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.